Characterization of size, structure and purity of serogroup X Neisseria meningitidis polysaccharide, and development of an assay for quantification of human antibodies

Vaccine

Volumn 30, Issue 40, 2012, Pages 5812-5823

  Xie, Ouli ^a   Bolgiano, Barbara ^b   Gao, Fang ^b   Lockyer, Kay ^b   Swann, Carolyn ^b   Jones, Christopher ^b   Delrieu, Isabelle ^c   Njanpop Lafourcade, Berthe Marie ^c   Tamekloe, Tsidi Agbeko ^d   Pollard, Andrew J ^a   Norheim, Gunnstein ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c Agency of Preventive Medicine   (France)

^d Ministry of Health   (Togo)

Author keywords

HPAEC PAD; MALLS; Meningococcal disease; Neisseria meningitidis; NMR; Polysaccharide

Indexed keywords

ANTIBODY; BACTERIAL POLYSACCHARIDE; MENINGOCOCCUS VACCINE;

ANION EXCHANGE CHROMATOGRAPHY; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; COVALENT BOND; ENZYME LINKED IMMUNOSORBENT ASSAY; HETERONUCLEAR SINGLE QUANTUM COHERENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; INFECTION PREVENTION; MENINGOCOCCOSIS; MICROTITER PLATE ASSAY; MOLECULAR SIZE; MULTIANGLE LASER LIGHT SCATTERING; NEISSERIA MENINGITIDIS; NONHUMAN; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; PULSED AMPEROMETRIC DETECTION; QUANTITATIVE ANALYSIS; SPECTROSCOPY; THERMOSTABILITY; TOTAL CORRELATION SPECTROSCOPY;

ADOLESCENT; ADULT; AFRICA SOUTH OF THE SAHARA; ANTIBODIES, BACTERIAL; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR SEQUENCE ANNOTATION; MOLECULAR STRUCTURE; NEISSERIA MENINGITIDIS; POLYSACCHARIDES, BACTERIAL; SEROTYPING; YOUNG ADULT;

EID: 84864808981     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.032     Document Type: Article

References (54)

1. Boisier P., Nicolas P., Djibo S., Taha M.K., Jeanne I., Mainassara H.B., et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007, 44:657-663.
2. Delrieu I., Yaro S., Tamekloe T.A., Njanpop-Lafourcade B.M., Tall H., Jaillard P., et al. Emergence of epidemic Neisseria meningitidis serogroup X meningitis in Togo and Burkina Faso. PLoS One 2011, 6:e19513.
3. Gagneux S.P., Hodgson A., Smith T.A., Wirth T., Ehrhard I., Morelli G., et al. Prospective study of a serogroup X Neisseria meningitidis outbreak in northern Ghana. J Infect Dis 2002, 185:618-626.
4. WHO Intercountry Support Team. Meningitis Weekly Bulletin, Week 20, 2010. Ouagadougou, Burkina Faso; 2011.
5. WHO Inter country Support Team. Meningitis Weekly Bulletin, Week 31-34, 2011. Ouagadougou, Burkina Faso; 2011.
6. Lewis R. Meningococcal meningitis serogroup X: a new player in Ugandan epidemiology. WHO Health Action Crisis 2006, 6.
7. Mutonga D.M., Pimentel G., Muindi J., Nzioka C., Mutiso J., Klena J.D., et al. Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. Am J Trop Med Hyg 2009, 80:619-624.
8. Materu S., Cox H.S., Isaakidis P., Baruani B., Ogaro T., Caugant D.A. Serogroup X in meningococcal disease, Western Kenya. Emerg Infect Dis 2007, 13:944-945.
9. Urwin R., Maiden M.C. Multi-locus sequence typing: a tool for global epidemiology. Trends Microbiol 2003, 11:479-487.
10. Balmer P., Borrow R. Serologic correlates of protection for evaluating the response to meningococcal vaccines. Expert Rev Vaccines 2004, 3:77-87.
11. Goldschneider I., Gotschlich E.C., Artenstein M.S. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med 1969, 129:1307-1326.
12. Andrews N., Borrow R., Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003, 10:780-786.
13. WHO Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A/C vaccines 1999, World Health Organization, Geneva, Switzerland.
14. Bundle D.R., Jennings H.J., Kenny C.P. Studies on the group-specific polysaccharide of Neisseria meningitidis serogroup X and an improved procedure for its isolation. J Biol Chem 1974, 249:4797-4801.
15. Bundle D.R., Smith I.C., Jennings H.J. Determination of the structure and conformation of bacterial polysaccharides by carbon 13 nuclear magnetic resonance. Studies on the group-specific antigens of Neisseria meningitidis serogroups A and X. J Biol Chem 1974, 249:2275-2281.
16. Yang Q., Jennings H.J. Purification of capsular polysaccharide. Meningococcal vaccines 2001, Humana Press, Totowa, New Jersey. 1st ed. A.J. Pollard, M.C. Maiden (Eds.).
17. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Frøholm L.O., et al. Production, characterization and control of MenB-vaccine: an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991, 14:67-79.
18. Leese A.J., Campagnari A.A., Bittner W.E., Apicella M.A. Increased resolution of lipopolysaccharides and lipooligosaccharides utilizing tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis. J Immunol Methods 1990, 126:109-117.
19. Vipond C., Mulloy B., Rigsby P., Bolgiano B. Evaluation of a candidate international standard for meningococcal serogroup C polysaccharide 2011, the MenC IS Working Group, WHO, Geneva, Switzerland, http://www.who.int/biologicals/expert_committee/BS2011.2169_Report_MenC_PS_30Aug2011.pdf [accessed 17.04.12].
20. Jones C., Lemercinier X. Full NMR assignment and revised structure for the capsular polysaccharide from Streptococcus pneumoniae type 15B. Carbohydr Res 2005, 340:403-409.
21. Jones C., Lemercinier X. Use and validation of NMR assays for the identity and O-acetyl content of capsular polysaccharides from Neisseria meningitidis used in vaccine manufacture. J Pharm Biomed Anal 2002, 30:1233-1247.
22. Jumel K., Ho M.M., Bolgiano B. Evaluation of meningococcal C oligosaccharide conjugate vaccines by size-exclusion chromatography/multi-angle laser light scattering. Biotechnol Appl Biochem 2002, 36:219-226.
23. Thiesen B., Greenwood B., Brieske N., Achtman M. Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein. Vaccine 1997, 15:209-219.
24. Arakere G., Frasch C.E. Specificity of antibodies to O-acetyl-positive and O-acetyl-negative group C meningococcal polysaccharides in sera from vaccinees and carriers. Infect Immun 1991, 59:4349-4356.
25. Carlone G.M., Frasch C.E., Siber G.R., Quataert S., Gheesling L.L., Turner S.H., et al. Multicenter comparison of levels of antibody to the Neisseria meningitidis group A capsular polysaccharide measured by using an enzyme-linked immunosorbent assay. J Clin Microbiol 1992, 30:154-159.
26. Gheesling L.L., Carlone G.M., Pais L.B., Holder P.F., Maslanka S.E., Plikaytis B.D., et al. Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay. J Clin Microbiol 1994, 32:1475-1482.
27. Kubler-Kielb J., Coxon B., Schneerson R. Chemical structure, conjugation, and cross-reactivity of Bacillus pumilus Sh18 cell wall polysaccharide. J Bacteriol 2004, 186:6891-6901.
28. EMEA Note for guidance on validation of analytical procedures: text and methology (CPMP/ICH/381/95) 1995, European Medicines Agency.
29. Norheim G., Arne H.E., Caugant D.A., Namork E., Tangen T., Fritzsonn E., et al. Immunogenicity and bactericidal activity in mice of an outer membrane protein vesicle vaccine against Neisseria meningitidis serogroup A disease. Vaccine 2004, 22:2171-2180.
30. Plikaytis B.D., Turner S.H., Gheesling L.L., Carlone G.M. Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay. J Clin Microbiol 1991, 29:1439-1446.
31. Aitken A., Learmonth M.P. Protein determination by UV absorption. Protein protocols handbook 2002, Humana Press, Totowa, New Jersey. J.M. Walker (Ed.).
32. Karamian N.A., Waters P.F. Spectrophotometry as a tool for assaying endotoxins. J Pharm Sci 1977, 66:723-724.
33. Kiang J., Wang L.X., Tang M., Szu S.C., Lee Y.C. Simultaneous determination of glucosamine and glucosamine 4-phosphate in Lipid A with high-performance anion-exchange chromatography (HPAEC). Carbohydr Res 1998, 312:73-76.
34. Lemercinier X., Jones C. An NMR spectroscopic identity test for the control of the capsular polysaccharide from Haemophilus influenzae type b. Biologicals 2000, 28:175-183.
35. Robinson J.A., Apicella M.A. Isolation and characterization of Neisseria meningitidis groups A, C, X, and Y polysaccharide antigens. Infect Immun 1970, 1:8-14.
36. Churms S.C. Recent progress in carbohydrate separation by high-performance liquid chromatography based on hydrophilic interaction. J Chromatogr A 1996, 720:75-91.
37. Gotschlich E.C., Goldschneider I., Artenstein M.S. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969, 129:1367-1384.
38. Gotschlich E.C., Rey M., Triau R., Sparks K.J. Quantitative determination of the human immune response to immunization with meningococcal vaccines. J Clin Invest 1972, 51:89-96.
39. Bergfeld A.K., Claus H., Lorenzen N.K., Spielmann F., Vogel U., Muhlenhoff M. The polysialic acid-specific O-acetyltransferase OatC from Neisseria meningitidis serogroup C evolved apart from other bacterial sialate O-acetyltransferases. J Biol Chem 2009, 284:6-16.
40. Berry D.S., Lynn F., Lee C.H., Frasch C.E., Bash M.C. Effect of O acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect Immun 2002, 70:3707-3713.
41. Michon F., Huang C.H., Farley E.K., Hronowski L., Di J., Fusco P.C. Structure activity studies on group C meningococcal polysaccharide-protein conjugate vaccines: effect of O-acetylation on the nature of the protective epitope. Dev Biol (Basel) 2000, 103:151-160.
42. Fusco P.C., Farley E.K., Huang C.H., Moore S., Michon F. Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation. Clin Vaccine Immunol 2007, 14:577-584.
43. Richmond P., Borrow R., Findlow J., Martin S., Thornton C., Cartwright K., et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infect Immun 2001, 69:2378-2382.
44. Borrow R., Longworth E., Gray S.J., Kaczmarski E.B. Prevalence of de-O-acetylated serogroup C meningococci before the introduction of meningococcal serogroup C conjugate vaccines in the United Kingdom. FEMS Immunol Med Microbiol 2000, 28:189-191.
45. Longworth E., Fernsten P., Mininni T.L., Vogel U., Claus H., Gray S., et al. O-acetylation status of the capsular polysaccharides of serogroup Y and W135 meningococci isolated in the UK. FEMS Immunol Med Microbiol 2002, 32:119-123.
46. Gudlavalleti S.K., Datta A.K., Tzeng Y.L., Noble C., Carlson R.W., Stephens D.S. The Neisseria meningitidis serogroup A capsular polysaccharides O-3 and O-4 acetyltransferase. J Biol Chem 2004, 279:42765-42773.
47. Butler J.E. Solid supports in enzyme-linked immunosorbent assay and other solid-phase immunoassays. Methods Mol Med 2004, 94:333-372.
48. Joseph H., Balmer P., Bybel M., Papa T., Ryall R., Borrow R. Assignment of Neisseria meningitidis serogroups A, C, W135, and Y anticapsular total immunoglobulin G (IgG), IgG1, and IgG2 concentrations to reference sera. Clin Diagn Lab Immunol 2004, 11:1-5.
49. Guirola M., Carmenate T., Menendez T., Alvarez A., Gonzalez S., Guillen G. Comparison of three ELISA protocols to measure antibody responses elicited against serogroup C meningococcal polysaccharide in mouse, monkey and human sera. J Microbiol Methods 2006, 65:135-143.
50. Arakere G., Lee A.L., Frasch C.E. Involvement of phospholipid end groups of group C Neisseria meningitidis and Haemophilus influenzae type b polysaccharides in association with isolated outer membranes and in immunoassays. J Bacteriol 1994, 176:691-695.
51. Sondergard-Andersen J., Lauritzen E., Lind K., Holm A. Covalently linked peptides for enzyme-linked immunosorbent assay. J Immunol Methods 1990, 131:99-104.
52. Akinwolere O.A., Kumararatne D.S., Bartlett R., Goodall D.M., Catty D. Two enzyme linked immunosorbent assays for detecting antibodies against meningococcal capsular polysaccharides A and C. J Clin Pathol 1994, 47:405-410.
53. Sow S.O., Okoko B.J., Diallo A., Viviani S., Borrow R., Carlone G., et al. Immunogenicity and safety of a meningococcal A conjugate vaccine in Africans. N Engl J Med 2011, 364:2293-2304.
54. Pace D., Pollard A.J., Messonier N.E. Quadrivalent meningococcal conjugate vaccines. Vaccine 2009, 27(Suppl. 2):B30-B41.